EFV
Sponsors
Juan A. Arnaiz, Gilead Sciences, Michael Hoelscher, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Boehringer Ingelheim
Conditions
HIVHIV InfectionsHIV-1 InfectionHIV-infection/AidsHealthyHepatitis CInfection, Human Immunodeficiency VirusLipoatrophy
Phase 1
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
CompletedNCT01565889
Start: 2012-03-31End: 2013-11-30Updated: 2014-10-01
Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers
CompletedNCT02253823
Start: 2001-12-31Updated: 2014-10-01
Phase 2
A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen
CompletedNCT01714414
Start: 2012-12-31End: 2017-02-28Updated: 2018-03-07
Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
CompletedNCT01903031
Start: 2014-12-30End: 2016-10-10Updated: 2018-06-06
Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults
TerminatedNCT02415595
Start: 2015-05-12End: 2017-08-21Updated: 2018-09-19